Results 211 to 220 of about 123,913 (326)

Does Intravitreal Dopamine Agonist and Antagonist Administration Have Effects on the Brain? An Experimental Study in Rats. [PDF]

Eurasian J Med, 2022
Kocak MN, Ates O, Hacımuftuoglu A, Ates I, Tekin E, Ceylan O, Okkay U.   +6 more
europepmc   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Incidence of heart valve disease in women treated with the ergot-derived dopamine agonist bromocriptine. [PDF]

BMC Cardiovasc Disord, 2021
Clausen MF, Rørth R, Torp-Pedersen C, Westergaard LM, Weeke PE, Gislason G, Køber L, Fosbøl E, Kristensen SL.   +8 more
europepmc   +1 more source

Evaluation of preclinical antipsychotic models used to support first‐in‐human clinical trials

British Journal of Pharmacology, EarlyView.
Abstract Schizophrenia is regarded as a complex and heterogeneous psychiatric disorder, characterised by diverse symptoms and comorbidities, which complicate both clinical management and drug development. Current pharmacological treatment, primarily based on dopamine D2 receptor antagonism or partial agonism, which has not markedly progressed since the
Thi Viet Ha Nguyen, Declan P. McKernan, John P. Kelly   +2 more
wiley   +1 more source

Change in Insulin Sensitivity and Lipid Profile After Dopamine Agonist Therapy in Patients With Prolactinoma. [PDF]

Cureus, 2021
Khalil G, Khan FA, Jamal QM, Saleem A, Masroor H, Abbas K.   +5 more
europepmc   +1 more source

Oxidant-induced cardiomyocyte injury: Identification of the cytoprotective effect of a dopamine 1 receptor agonist using a cell-based high-throughput assay

, 2007
Csaba Szabó, György Dormán, Zoltán Tóth, Nóra V. Nagy, Petra Szoleczky, Katalin Módis, Domokos Gerő   +6 more
openalex   +2 more sources

Targeting the noradrenergic‐metabolic axis: A new strategy for sugar‐induced depression subtypes

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Lifestyle is closely related to major depressive disorder (MDD). Given the growing focus on the impact of diet on mental health, this study examined how dietary habits affect the pathophysiology of MDD. Experimental Approach Health check‐up data were analysed. Mice received sucrose under chronic unpredictable mild stress
Takatoshi Sakata, Kazuo Kunisawa, Masaya Hasegawa, Yumiko Seto, Aoi Ogawa, Hitomi Kurahashi, Yasuko Yamamoto, Masao Takemura, Hidetoshi Matunami, Tomoya Sugai, Noriki Kutsumura, Kuniaki Saito, Toshitaka Nabeshima, Akihiro Mouri   +13 more
wiley   +1 more source

Aripiprazole use as a cause of dopamine agonist failure in the treatment of prolactinomas. [PDF]

Endocr Oncol
Mignone E, Jukes AK, Valentine R, Allison R, De Sousa SMC.   +4 more
europepmc   +1 more source

The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis. [PDF]

BMC Endocr Disord, 2021
Zou Y, Li D, Gu J, Chen S, Wen X, Dong J, Jiang X.   +6 more
europepmc   +1 more source

Conclusion lessons from the novel D2 dopamine receptor, β2-adrenoceptor agonist, Viozan™: chronic obstructive pulmonary disease and drug development implications

, 2003
P. M. A. Calverley, E.T. Keating, Mitch Goldman, Frank E. Casty   +3 more
openalex   +1 more source